S-Space Graduate School of Convergence Science and Technology (융합과학기술대학원) Dept. of Molecular and Biopharmaceutical Sciences (분자의학 및 바이오제약학과) Journal Papers (저널논문_분자의학 및 바이오제약학과)
Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer
- Sim, Eun Ji; Ko, Kwang-Pil; Ahn, Choonghyun; Park, Sang Min; Surh, Young-Joon; An, Seokyung; Kim, Sung-Won; Lee, Min-Hyuk; Lee, Jong Won; Lee, Jeong Eon; Kim, Ku Sang; Yom, Cha Kyong; Kim, Hyun-Ah; Park, Sue K.
- Issue Date
- Breast Cancer Research and Treatment, Vol.184 No.2, pp.615-626
- Hereditary breast cancer syndrome; Familial breast cancer; BRCAmutation; Isoflavones; Soy; Molecular subtypes
- Purpose We investigated the association between isoflavone (ISF) intake and hereditary breast cancer (BC) risk, particularly by molecular subtype, in East-AsianBRCA1/2mutation carriers and non-carriers at a high risk of hereditary breast cancer (i.e., family history of BC (FHBC) and early-onset BC [EOBC, age < 40 years]). Methods The association between ISF intake and BC risk by molecular subtypes was assessed in 1709 participants (407BRCA1/2carriers, 585 FHBC non-carriers, 586 EOBC non-carriers, and 131 unaffected non-carriers) from the Korean Hereditary Breast Cancer Study using hazard ratios (HRs) and 95% confidence intervals (CIs) in weighted Cox regression models. Daily ISF intake was assessed using a validated food frequency questionnaire. We evaluated gene-environment interactions betweenBRCA1/2mutation and ISF intake in 1604 BC cases by calculating the case-only odds ratios (CORs) and 95% CIs in logistic regression models. Results ISF intake was inversely associated with luminal A BC risk inBRCA2mutation carriers and FHBC non-carriers (HR = 0.14, 95% CI = 0.04-0.50 for high intake [ISF intake >= 15.50 mg/day]; HR = 0.27, 95% CI = 0.11-0.69 for high intake, respectively). We observed a reduced risk of triple negative BC (TNBC) inBRCA1carriers and FHBC non-carriers (HR = 0.09, 95% CI = 0.02-0.40 for high intake; HR = 0.19, 95% CI = 0.05-0.69 for high intake, respectively). In the case-only design, an interaction betweenBRCA1mutation carrier status and ISF intake emerged in TNBC patients (COR = 0.39, 95% CI = 0.16-0.95). Conclusions This study suggests that ISF intake is inversely associated with BC risk in women at high risk of hereditary BC and that the effect could differ by molecular subtypes.
- Files in This Item: There are no files associated with this item.